Use of haploidentical (haplo) donors for hematopoietic cell transplantation (HCT) has significantly increased in the last decade. The major advantage with this strategy is universal availability and faster acquisition of the donor, along with affordability and provision of immunotherapy in post-transplantation period. Historically, haplo-HCT was associated with compromised outcomes because of high rates of graft-versus-host disease and graft failure, but after the development of a post-transplantation high-dose cyclophosphamide strategy, which results in selective T-cell depletion, these issues have been addressed to a large extent. Nevertheless, graft failure, high treatment-related mortality due to graft-versus-host disease, infections, delayed immune reconstitution, and disease relapse remain significant concerns. As the experience with haplo-HCTs grows, the clinical outcomes are becoming more at par with those seen with fully matched unrelated donor allogeneic HCTs.

**INTRODUCTION**

Allogeneic hematopoietic cell transplantation (allo-HCT) is considered the only curative option for patients with various benign as well as malignant hematologic disorders.¹ There is remarkable polymorphism in the human leukocyte antigen (HLA) gene complex, and an HLA-matched sibling donor is available in only 30% to 35% of patients.² In the registries, the odds of finding a matched unrelated donor (MUD) range from 79% for white patients to 20% in minority ethnic groups.³ On the other hand, related donors who share at least one haplotype are available for nearly all individuals. According to an estimate, 95% of the patients have at least one haploidentical (haplo) donor, and on average there are 2.7 haplo donors available for each recipient.⁴ This universal availability makes haplo-HCT a particularly feasible option for patients who lack an otherwise fully matched donor. In this review, we summarize the historical and recent developments relating to haplo-HCT, with a particular focus on challenges in developing such a program in Pakistan.

**REVIEW OF LITERATURE**

The first successful HCT was performed from an identical twin donor by Thomas et al⁵ in the late 1950s. In 1968, attempts were successful for allo-HCT from a non-twin sibling donor.⁶ The first successful unrelated donor (UD) transplantation took place in 1973. Compelled by the lack of universal availability of donors for many patients, haplo-HCT was explored.⁷ This strategy is especially helpful for ethnic minorities and resource-constrained countries where unrelated donor registries are lacking.

**Haplo-HCT With Myeloablative Conditioning Regimens**

The early results of haplo-HCT were marred by the high incidence of graft failure, graft-versus-host disease (GVHD), delayed immune reconstitution, and life-threatening infections during periods of prolonged neutropenia.⁸,⁹ A pioneer study by Anasetti et al¹⁰ at the Fred Hutchinson Cancer Center showed that haplo-HCT after myeloablative (MA) conditioning is associated with increased incidence of graft failure and GVHD. This study revealed that results with a 5/6 HLA-matched donor were almost the same as with a 6/6 HLA-matched donor. However, the results with more than one antigen-mismatched graft were not encouraging. A study of 35 patients with up to three antigen-mismatched grafts using MA conditioning by Powles et al¹¹ revealed high incidence of GVHD (80%) with high mortality rate, thus rejecting the mismatched transplants as a feasible option.

The International Blood and Marrow Transplant Registry¹² studied 2,000 patients including both 6/6 HLA-matched and partially mismatched...
donors and concluded that there is high transplantation-related mortality (TRM) associated with mismatched transplants in low/standard risk diseases, but there was a negligible difference in TRM of 6/6 HLA-matched or partially mismatched transplants in high-risk patients. Another study from Japan by the Japanese Society for HCT showed that there was a fractional difference between the outcomes of high-risk patients with fully or partially matched donor transplants, but this difference was significant in standard-risk patients.

A Japanese study by Kaida et al followed 351 patients who underwent haplo-HCT. Of those, 100 patients received MA conditioning and 251 received reduced-intensity conditioning (RIC). MA conditioning resulted in higher rates of GVHD (36%) compared with RIC (20%). Five-year overall survival (OS) was also lower with MA conditioning (30%) compared with 40% seen in patients who had received RIC (Table 1).

Huang et al studied 21 patients and showed that granulocyte colony-stimulating factor (G-CSF)–primed bone marrow grafts from haploidentical donors without in vitro removal of T cells may have better results. Santarone et al also concluded that G-CSF–mobilized bone marrow harvest from haploidentical donors is a better solution for the patients who do not have fully HLA-matched donors. Many researchers demonstrated that removal of T cells from the graft attained by bone marrow harvest or peripheral blood stem cells (PBSCs) results in significantly decreased incidence of acute as well as chronic GVHD.

Researchers from China compared MA conditioning regimens with antithymocyte globulin (ATG) for matched related donor (MRD) and haplo transplantations and found relatively lower incidence of acute GVHD among the partially mismatched/haplo transplantation group, probably due to in vivo T-cell depletion caused by ATG. Haplo-HCT with T-cell depletion has been reported to have high incidence of TRM, mainly as the result of infectious complications and conditioning toxicity. Post-transplantation cyclophosphamide (PT/Cy) has reduced TRM incidence by using T-cell–replete haplo grafts.

Solomon et al studied 20 patients with myeloid malignancies who were administered MA conditioning with busulphan/fludarabine/cyclophosphamide. They observed encouraging results, with incidence of acute GVHD, chronic GVHD, and 1-year OS being 10%, 5%, and 69%, respectively (Table 1). In another report from the same group, 30 patients underwent haplo-HCT using a total-body irradiation–based MA preparative regimen. All evaluable patients achieved sustained complete donor T-cell and myeloid chimerism by day 30. The 2-year TRM was only 5%, and after a median follow-up of 17 months, the estimated 2-year OS and progression-free survival were 84% and 76%, respectively.

In another report, Raiola et al studied 50 patients, with the great majority having myeloid and a few having lymphoid malignancies. Patients were administered MA conditioning, T-cell–replete grafts, and two doses of PT/Cy on day +3 and day +5 post–haplo-HCT. Incidence of acute and chronic GVHD was 12% and 10%, respectively, with relapse rate of 22% and 18% nonrelapse mortality (NRM; Table 1).

Pingali et al from MD Anderson Cancer Center followed 84 patients who received bone marrow–harvested graft after melphalan-based conditioning providing a potentially more ablative effect. Only four patients were administered PBSCs. For the patients who underwent first transplantation, median OS was 25.6 months, and the patients with second transplantation had an OS of 6.5 months. NRM was 9%, and relapse rate was 24.3%. For patients with myeloid malignancies, the results were comparable with MRD or MUD transplant, but neutrophil and platelet engraftment was longer in these patients, probably because of using bone marrow harvest as the source of stem cells.

Nonmyeloablative Conditioning Regimens

Despite the fact that MA conditioning with megadoses of CD34+ cells (> 10^6/kg) for haplo-HCT achieved considerable success, these regimens were not without disadvantages, including high TRM, slow engraftment/graft failure especially if megadoses of CD34+ cells were not achievable, delayed immune reconstitution, and increased GVHD mainly because of an increased number of T cells in G-CSF–mobilized grafts. Nonmyeloablative (NMA) conditioning regimens have reduced the conditioning toxicity and shortened the neutropenic period, resulting in wider application of this mode to the elderly population as well.

Munchel et al at John Hopkins studied 210 patients who underwent...
Table 1. Studies With MA Conditioning Regimens for Haplo-HCT

| Author          | Year | No. of Patients | Median Age (years) | Diagnosis                | Conditioning Regimens              | GVHD Prophylaxis | Neutrophil Engraft (days) | Platelet Engraft (days) | GVHD (%) |
|-----------------|------|----------------|-------------------|--------------------------|------------------------------------|------------------|--------------------------|--------------------------|-----------|
| Kadia et al.   | 2011 | 351            | 39                | AML/ALL/ MDS/ NHL/others | Flu/AraC/Cy/TBI = 100 (haplo-full) | MTX, MMF, Tacro, MP | 13 (haplo-full)          | 33 (haplo-full)          | 36 (haplo-full) |
| Santarone et al.| 2011 | 40             | 32                | AML/ALL/ CML/ NHL       | NA ATGCSA/MTX/MMF/basiliximab       | 22               | 27                       | —                        | 23 (haplo-mini) |
| Huang et al.   | 2012 | 21             | 24                | AML/ALL/ MDS/ NHL       | Bu/Cy/ATG:14 TBI/Cy/ATG:6          | CSA/MTX/MMF      | 16.5                     | 20                       | 33.8 (haplo-mini) |
| Pingali et al. | 2016 | 84             | 46                | AML/ALL/ MDS/ CML/ NHL  | Flu/Mel ± thiotepa                 | CSA/MMF/PTCy     | 18                       | 25                       | 32.6 (haplo-mini) |
| Raiola et al.  | 2013 | 50             | 42                | AML/ALL/ CML/ NHL/ MPF/ MPD | TT/Bu/Flu = 35 TBI/Flu = 15 | CSA/MMF/PTCy + 3+5 | 18                       | 23                       | 12 (haplo-mini)   |

(Continued on following page)
Table 1. Studies With MA Conditioning Regimens for Haplo-HCT (Continued)

| Author             | Year | No. of Patients | Median Age (years) | Diagnosis          | Conditioning Regimens | GVHD Prophylaxis | Neutrophil Engraft (days) | Platelet Engraft (days) | GVHD (%) | Acute II-IV | Acute III-IV | Chronic | OS                      |
|--------------------|------|----------------|--------------------|--------------------|-----------------------|-------------------|--------------------------|--------------------------|-----------|-------------|-------------|---------|-------------|
| Symons et al19     | 2011 | 30             | 43                 | AML/ALL/ CML/ NHL/HD | Bu/Cy = 27            | Cy/MMF/ Tacro     | 25                       | 32                       | 14        | 7.3         | 13          | 40%      | at 1 year                             |
| Solomon et al20    | 2013 | 20             | 44                 | AML/ALL/ CML/ CLL/ NHL/HD | Bu/Flu/Cy         | Tacro/MMF/ PTCy +3+4 | 16                       | 27                       | 30        | 10          | 35          | 69%      | at 1 year                             |

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; AraC, cytarabine; ATG, antithymocyte globulin; CSA, cyclosporin; Bu, busulphan; CML, chronic myeloid leukemia; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; haplo, haploidentical; HCT, hematopoietic cell transplantation; HD, Hodgkin disease; MA, myeloablative; MDS, myelodysplastic syndrome; Mel, melphelan; MMF, mycophenolate mofetil; MP, methylprednisolone; MPD, myeloproliferative disorders; MTX, methotrexate; NA, not applicable; NHL, Non-Hodgkin lymphoma; OS, overall survival; PMF, primary myelofibrosis; PTCy, post-transplantation cyclophosphamide; Tacro, tacrolimus; TBI, total-body irradiation.
Table 2. Studies With Nonmyeloablative Conditioning Regimens for Haplo-HCT

| Author          | Year | No. of Patients | Median Age (years) | Diagnosis | Conditioning Regimens | GVHD Prophylaxis | Neutrophil Engraft (days) | Platelets Engraft (days) | GVHD (%)  | Acute II-IV | Acute III-IV | Chronic | OS          |
|-----------------|------|-----------------|--------------------|-----------|-----------------------|------------------|--------------------------|--------------------------|------------|-------------|-------------|----------|-------------|
| Munchel et al   | 2011 | 210             | 52                 | AML/ALL/ CML/CLL/ MDS/NHL/ HD/MM/ PNH | Flu/Cy/TBI       | MMF/Tacro/ PTCy   | 15                       | 24                       | 27         | 5           | 15          |          | 41% at 3 years |
| Lee et al       | 2011 | 83              | 26                 | AML/ALL/ MDS | Bu/Flu/ATG            | CSA/MTX          | 13.5                     | 17                       | 20         | 7           | 34          | CR1: 60% | CR2/3: 41% |
| Luznik et al    | 2008 | 68              | 46                 | AML/ALL/ CML/CLL/ MDS/NHL/ HD/MM/ PNH | Cy/Flu/TBI       | Tacrolimus/MMF/ PTCy | 15                       | 24                       | 34         | 6           | 5 (1 dose of PTCy) | 36% at 12 years |
| Brunstein et al | 2011 | 50              | 48                 | AML/ALL/ biphenotypic/ NHL/HD | Cy/Flu/TBI       | Tacrolimus/MMF/ PTCy | 16                       | 24                       | 32         | —           | —           | —        | 62% at 1 year |
| Raj et al       | 2014 | 55              | 49                 | AML/ALL/ CML/CLL/ NHL/HD/AA | Cy/Flu/TBI       | Tacrolimus/MMF/ PTCy | 17                       | 21                       | 53         | 8           | 18          | 48% at 2 years |
| Bhamidipati et al | 2014 | 18              | 41                 | AML/ALL/ CL/NHL/ AA | Cy/Flu/TBI       | Tacrolimus/MMF/PT/ Cy | 15                       | 18                       | 41         | 17          | 8           | 62% at 1 year |

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; AraC, cytarabine; ATG, antithymocyte globulin; Bu, busulphan; CML, chronic myeloid leukemia; CSA, cyclosporin; CR, complete remission; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; haplo, haploidentical; HCT, hematopoietic cell transplantation; HD, Hodgkin disease; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX, methotrexate; NH, Non-Hodgkin lymphoma; OS, overall survival; PTCy, post-transplantation cyclophosphamide; Tacro, tacrolimus; TBI, total-body irradiation.
NMA conditioning regimen for haplo-HCT followed by PT/Cy. The incidence of acute GVHD (II to IV) was 27%, chronic GVHD was 13%, and NRM was 18%, but the cumulative incidence of relapse-associated mortality was unacceptably high (55%; Table 2).

Lee et al30 reported the outcomes of 83 patients who underwent haplo-HCT. After a median follow-up time of 26.6 months (range, 16.8 to 78.8 months), the OS for patients with acute leukemias in first complete remission, second or third complete remission, and refractory leukemia was 60%, 41%, and 9%, respectively (Table 2).30 Raj et al32 reported the outcome of 55 patients who underwent haplo-HCT at four transplantation centers using RIC and PBSC grafts followed by PT/Cy. The incidence of acute GVHD grade II, III, IV, and chronic GVHD was 53%, 8%, 0%, and 18%, respectively. OS was 48% at a median follow-up of 509 days (Table 2).

Luznik et al1 and Bhamidipati et al33 also used an NMA conditioning regimen for their patients undergoing haplo-HCT. Luznik et al1 reported 50% OS at 4.1 years median follow-up, and Bhamidipati et al33 reported 62% OS at 1 year. Significant clinical studies with MA/NMA conditioning revealed results comparable to matched sibling donor (MSD)/MRD/MUD transplants, but additional validation of the data is awaited.34-86

HAPLOIDENTICAL STEM-CELL TRANSPLANTATION: PAKISTANI PERSPECTIVE

Pakistan is the sixth most populous country, with more than 200 million inhabitants. The country is facing many challenges, including population explosion, illiteracy, lack of nationwide health...
infrastructure, economic crises, and, last but not the least, war on terrorism.

The incidence of aplastic anemia (AA) in Asia is two- to three-fold higher than the incidence in any other part of the world.\textsuperscript{87} In Pakistan, more than 50% of patients in any hematology clinic have a diagnosis of AA.\textsuperscript{88} Etiology of the high incidence of AA includes both genetic and acquired factors.\textsuperscript{89} Host genetic factors, especially short telomere length, have been recognized to be one of the culprits. Environmental factors responsible for increased incidence of AA include pesticides, benzene, arsenic, and many viruses. In Pakistan, the rural population is at a greater risk of AA compared with the urban population, because, being an agricultural country, people living in villages have increased exposure to pesticides.\textsuperscript{90} Pesticides have been reported to be associated with hematologic malignancies as well. Exposure to excessive radiation also increases the risk of acute and chronic leukemia.

Among genetic disorders, the most frequently encountered hemoglobinopathy is β-thalassemia major. There are more than 100,000 patients with β-thalassemia major in the country, and, despite increasing awareness about prevention, 5,000 annual births are still being reported.\textsuperscript{91} HCT is the only curative option for AA, β-thalassemia major, and poor-risk leukemias.

**CURRENT STATUS OF HCT IN PAKISTAN**

In Pakistan, only eight well-established centers are carrying out hemopoietic stem-cell transplantation, and few smaller centers are also being developed. The first bone marrow transplantation center was established in 1999 in Karachi (National Institute of Blood Disease) followed by Armed Forces Bone Marrow Transplant Centre in 2001, which has emerged as the largest center of the country. Aga Khan University Hospital was started in 2004. A total of 1,589 transplantations had been carried out by 2017 (data collected by personal communication), out of which 256 were autologous. The major indications for transplantation were β-thalassemia major (603), followed by aplastic anemia (540) and acute leukemia (169). The patient population comprised both children and adults (Fig 1).

All patients received stem-cell grafts from matched related donors. However, these transplantations account for a small percentage of the potential candidates requiring HCT in our country.

**MAJOR INDICATIONS FOR HCT IN PAKISTAN**

Major indications for HCT in our country are listed in Table 3. Most of the patients being transplanted belong to the groups of mentioned diseases, but few very rare diseases have also undergone HCT.

**HAPLO-HCT IN PAKISTAN**

Currently only two larger transplantation centers of Pakistan are carrying out haplo-HCT. A total of 47 haplo-HCT procedures have been performed in the country for various indications, including aplastic anemia, β-thalassemia major, immunodeficiency states, and acute leukemias (Fig 2).

**CURRENT CHALLENGES FOR HCT IN PAKISTAN**

Less than 10% of the potential candidates requiring HCT can actually undergo the procedure for the following reasons:

1. Lack of specialized centers.
2. Lack of trained human resources, including doctors, nurses, pharmacists, technologists, and paramedics. Low HCT team density: there are just five HCT teams for a population of 200 million (ie, 0.025 teams/ million), compared with Europe, where the ratio is 14.43/million, and Eastern Mediterranean countries, with a ratio of 1.55/million population.\textsuperscript{92}
3. Limited availability of specialized instruments.
4. High cost involved in the procedure.
5. Limited availability of fully HLA-matched donors.

![Fig 2. Major indications for haploidentical transplantation in Pakistan. CML, chronic myeloid leukemia; HLH, haemophagocytic lymphohistiocytosis; MDS, myelodysplastic syndrome; SCID, severe combined immunodeficiency diseases.](jgo.org)
6. Nonavailability of MUD registry and cord blood banks.
7. Extremely high cost required for approaching international MUD registries and cord blood banks.
8. Lack of infrastructure and government support for the national transplant registry.

Because of these constraints, haplo-HCT seems to be the most feasible transplantation option for patients who do not have a fully HLA-matched donor.

CONCLUSION AND FUTURE DIRECTIONS

Haplo-HCT seems to be a feasible way to provide transplantation for patients who need allo-HCT but lack a fully HLA-matched donor. This seems particularly true for the developing countries, where lack of resources poses a major challenge. The use of high-dose cyclophosphamide day +3 and +4 post–haplo-HCT is an effective strategy to deplete alloreactive T cells responsible for GVHD and graft rejection. This does not harm stem cells in the graft, which are resistant to cyclophosphamide because of high levels of the enzyme aldehyde dehydrogenase. Ongoing studies comparing haplo-HCT with cord blood transplantations or MUD transplantations will shed light on preference of haplo donors if an MRD is not available.

DOI: https://doi.org/10.1200/JGO.18.00130
Published online on jgo.org on December 6, 2018.

AUTHOR CONTRIBUTIONS

Conception and design: Mehreen A. Khan, Qaiser Bashir, Qamar-un-Nisa Chaudhry, Parvez Ahmed
Administrative support: Tariq M. Satti
Collection and assembly of data: Tariq M. Satti, Syed K. Mahmood
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Mehreen A. Khan
No relationship to disclose

Qaiser Bashir
Consulting or Advisory Role: Takeda, Spectrum Pharmaceuticals, Kite Pharma, Amgen
Research Funding: Takeda (Inst), Celgene

Qamar-un-Nisa Chaudhry
No relationship to disclose

Parvez Ahmed
No relationship to disclose

Tariq M. Satti
No relationship to disclose

Syed K. Mahmood
No relationship to disclose

ACKNOWLEDGMENT

We thank the staff of the research and publication department of Armed Forces Bone Marrow Transplant Centre/National Institute of Blood and Marrow Transplant for their support.

Affiliations

Mehreen A. Khan, Qamar-un-Nisa Chaudhry, Tariq M. Satti, and Syed K. Mahmood, Armed Forces Bone Marrow Transplant Centre/National Institute of Blood and Marrow Transplant, Rawalpindi; Parvez Ahmed, Quaid-e-Azam International Hospital, Islamabad, Pakistan; and Qaiser Bashir, MD Anderson Cancer Centre, Houston, TX.

REFERENCES

1. Luznik L, O’Donnell PV, Symons HJ, et al: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641-650, 2008
2. Copelan EA: Hematopoietic stem-cell transplantation. N Engl J Med 354:1813-1826, 2006
3. Gragert L, Eapen M, Williams E, et al: HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371:339-348, 2014
4. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, González-Llano O, et al: Haploidentical bone marrow transplantation in 2015 and beyond. Curr Oncol Rep 17:57, 2015

5. Thomas ED, Lochte HL Jr, Cannon JH, et al: Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38:1709-1716, 1959

6. Gatti RA, Meuwissen HJ, Allen HD, et al: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2:1366-1369, 1968

7. Speck B, Zwaan FE, van Rood JJ, et al: Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HL-A-identical unrelated donor. Transplantation 16:24-28, 1973

8. Anasetti C, Beatty PG, Storb R, et al: Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 29:79-91, 1990

9. Kernan NA, Flomenberg N, Dupont B, et al: Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 43:842-847, 1987

10. Anasetti C, Amos D, Beatty PG, et al: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320:197-204, 1989

11. Powles RL, Morgenstern GR, Kay HE, et al: Mismatched family donors for bone-marrow transplantation as treatment for acute leukemia. Lancet 1:612-615, 1983

12. Szydlo R, Goldman JM, Klein JP, et al: Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15:1767-1777, 1997

13. Kanda Y, Chiba S, Hirai H, et al: Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102:1541-1547, 2003

14. Kaida K, Ikegame K, Yoshihara S, et al: Unmanipulated HLA-haploidentical (2-3 antigen-mismatched) stem-cell transplantation using myeloablative or reduced-intensity preconditioning regimen. Blood 118:4117, 2011

15. Santarone S, De Angelis G, Di Bartolomeo E, et al: Non T-depleted bone marrow transplantation from haploidentical related donor in hematological malignancies. Blood 114:2291, 2009

16. Huang W, Li H, Gao C, et al: Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Transfusion 52:1354-1362, 2012

17. Pingali SR, Milton D, di Stasi A, et al: Haploidentical transplantation for advanced hematologic malignancies using melphalan-based conditioning–mature results from a single center. Biol Blood Marrow Transplant 20:S40-S41, 2014

18. Raiola AM, Dominietto A, Ghiso A, et al: Unmanipulated haploidentical bone marrow transplantation and post-transplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19:117-122, 2013

19. Symons HJ, Chen AR, Luznik L, et al: Myeloablative haploidentical bone marrow transplantation with T cell replete grafts and post-transplant cyclophosphamide: Results of a phase II clinical trial. Blood 118:4151, 2011

20. Solomon SR, Sizemore CA, Sanacore M, et al: Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: Results of a prospective phase II trial. Biol Blood Marrow Transplant 18:1859-1866, 2012

21. Buckley RH, Schiff SE, Schiff RI, et al: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340:508-516, 1999
22. Lu D-P, Dong L, Wu T, et al: Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107:3065-3073, 2006
23. Ciurea SO, Mulanovich V, Saliba RM, et al: Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18:1835-1844, 2012
24. Ciurea SO, Saliba R, Rondon G, et al: Reduced-intensity conditioning using fludarabine, melphalan and thiopeta for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45:429-436, 2010
25. Mulanovich VE, Jiang Y, de Lima M, et al: Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. Am J Blood Res 1:98-105, 2011
26. Solomon SR, Sizemore C, Zhang X, et al: TBI-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 21:1299-1307, 2015
27. Aversa F, Terenzi A, Tabilio A, et al: Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23:3447-3454, 2005
28. Chang YJ, Huang XJ: Haploidentical bone marrow transplantation without T-cell depletion. Semin Oncol 39:653-663, 2012
29. Munchel AT, Kasamon YL, Fuchs EJ: Treatment of hematological malignancies with non-myeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol 24:359-368, 2011
30. Lee KH, Lee JH, Lee JH, et al: Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 118:2609-2617, 2011
31. Brunstein CG, Fuchs EJ, Carter SL, et al: Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118:282-288, 2011
32. Raj K, Pagliuca A, Bradstock K, et al: Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 20:890-895, 2014
33. Bhamidipati PK, DiPersio JF, Stoker-Goldstein K, et al: Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant 49:1124-1126, 2014
34. Im HJ, Koh KN, Choi ES, et al: Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant 19:754-759, 2013
35. Stanhellini MT, Locatelli F, Ciceri F, et al: Haploidentical hematopoietic stem cell transplantation is a therapeutic option in patients with refractory acquired aplastic anemia: A survey by the Severe Aplastic Anemia Working Party (SAAWP) and Pediatric Diseases Working Party (PDWP) of the EU. Bone Marrow Transplant 49:S91, 2014
36. Takahashi SY, Kawashima N: Hematopoietic stem cell transplantation from an alternative donor for childhood aplastic anemia: HLA haploidentical family donor vs HLA mismatched unrelated donor. Bone Marrow Transplant 49:S124, 2014
37. Zecca M, Strocchio L, Pagliara D, et al: HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. Biol Blood Marrow Transplant 20:571-576, 2014
38. Tolar J, Sodani P, Symons H: Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplant 50:619-627, 2015
39. Bolaños-Meade J, Fuchs EJ, Luznik L, et al: HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120:4285-4291, 2012

40. Fuchs EJ: Haploidentical transplantation for hematologic malignancies: Where do we stand? Hematology (Am Soc Hematol Educ Program) 2012:230-236, 2012

41. O’Donnell PV, Luznik L, Jones RJ, et al: Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8:377-386, 2002

42. Berger M, Lanino E, Cesaro S, et al: Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: An AIEOP-GITMO retrospective multicenter study. Biol Blood Marrow Transplant 22:902-909, 2016

43. Storek J, Mohty M, Boelens JJ: Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:959-970, 2015

44. Ruutu T, Gratwohl A, de Witte T, et al: Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 49:168-173, 2014 [Erratum: Bone Marrow Transplant 49:319, 2014]

45. Di Ianni M, Falzetti F, Carotti A, et al: Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117:3921-3928, 2011

46. Lu SY, Liu KY, Liu DH, et al: High frequencies of CD62L+ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic hematopoietic stem cell transplantation. Clin Exp Immunol 165:264-277, 2011

47. Lazarus HM, Koc ON, Devine SM, et al: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11:389-398, 2005

48. Ball LM, Bernardo ME, Roelofs H, et al: Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110:2764-2767, 2007

49. Liu K, Chen Y, Zeng Y, et al: Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells Dev 20:1679-1685, 2011

50. Mehta J, Singhal S, Gee AP, et al: Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: Single-center experience of 201 patients. Bone Marrow Transplant 33:389-396, 2004

51. Handgretinger R, Klingebiel T, Lang P, et al: Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27:777-783, 2001

52. Klingebiel T, Handgretinger R, Lang P, et al: Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 18:181-192, 2004

53. Wu BY, Guo KY, Song CY, et al: Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation. Bone Marrow Transplant 26:691-693, 2000

54. Lewalle P, Triffet A, Delforge A, et al: Donor lymphocyte infusions in adult haploidentical transplant: A dose finding study. Bone Marrow Transplant 31:39-44, 2003

55. Pati AR, Godder K, Lamb L, et al: Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 15:979-981, 1995

56. Or R, Hadar E, Bitan M, et al: Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 12:1295-1301, 2006
57. Huang X-J, Liu D-H, Liu K-Y, et al: Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 92:414-417, 2007

58. Huang X-J, Liu D-H, Liu K-Y, et al: Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 28:276-283, 2008

59. Wang Y, Liu DH, Xu LP, et al: Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: A retrospective risk-factor analysis. Bone Marrow Transplant 47:1099-1104, 2012

60. Liu KY, Chen YH, Liu DH, et al: A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. Bone Marrow Transplant 42:535-539, 2008

61. Seggewiss R, Einsele H: Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: An update. Blood 115:3861-3868, 2010

62. Feuchtinger T, Opherk K, Bethge WA, et al: Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116:4360-4367, 2010

63. Comoli P, Basso S, Labirio M, et al: T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 40:68-70, 2008

64. Comoli P, Schilham MW, Basso S, et al: T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother 31:529-536, 2008

65. Chang YJ, Luznik L, Fuchs EJ, et al: How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol 9:35, 2016

66. Wang Y, Chang YJ, Xu LP, et al: Who is the best donor for a related HLA-haplotype-mismatched transplant? Blood 124:843-850, 2014

67. Luo Y, Xiao H, Lai X, et al: T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124:2735-2743, 2014

68. McCurdy SR, Kanakry JA, Showel MM, et al: Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 125:3024-3031, 2015

69. Stern M, Brand R, de Witte T, et al: Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant 8:2149-2157, 2008

70. Wang Y, Liu DH, Liu KY, et al: Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: Nine years of experience at a single center. Cancer 119:978-985, 2013

71. Ciurea SO, Bayraktar UD: “No donor”? Consider a haploidentical transplant. Blood Rev 29:63-70, 2015

72. Peccatori J, Forcina A, Clerici D, et al: Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 29:396-405, 2015

73. Wang Y, Liu Q-F, Xu L-P, et al: Haploidentical vs identical-sibling transplant for AML in remission: A multicenter, prospective study. Blood 125:3956-3962, 2015

74. Chang YJ, Xu LP, Liu DH, et al: The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation. Pediatr Blood Cancer 53:1100-1106, 2009
75. Chang Y-J, Zhao X-Y, Xu L-P, et al: Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: A prospective study with randomly assigned training and validation sets. J Hematol Oncol 8:84, 2015

76. Kasamon YL, Luznik L, Leffell MS, et al: Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: Effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16:482-489, 2010

77. Aversa F, Velardi A, Tabilio A, et al: Haploidentical stem cell transplantation in leukemia. Blood Rev 15:111-119, 2001

78. Lang P, Bader P, Schumm M, et al: Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol 124:72-79, 2004

79. Kawano Y, Takaue Y, Watanabe A, et al: Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood 92:3132-3130, 1998

80. Peters C, Matthes-Martin S, Fritsch G, et al: Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: Evaluation of early monitoring of engraftment. Leukemia 13:2070-2078, 1999

81. Passweg JR, Kühne T, Gregor M, et al: Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplant 26:1033-1036, 2000

82. Rizzieri DA, Koh LP, Long GD, et al: Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25:690-697, 2007

83. Schmitz N, Bekmac M, Bacigalupo A, et al: Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 90:643-648, 2005

84. Gallardo D, De La Cámara R, Nieto JB, Espigado I, Iriondo A, Jiménez-Velasco A, et al: Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 94:1282-1288, 2009

85. Anasetti C, Logan BR, Lee SJ, et al: Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367:1487-1496, 2012

86. Siddiq S, Pamphilon D, Brunskill S, et al: Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 1:CD006406, 2009

87. Issaragrisil S, Kaufman DW, Anderson T, et al: The epidemiology of aplastic anemia in Thailand. Blood 107:1299-1307, 2006

88. Shamsi Ts, Hashmi K, Adil S, et al: The stem cell transplant program in Pakistan--the first decade. Bone Marrow Transplant 42:S114-S117, 2008 (suppl 1)

89. Young NS, Kaufman DW: The epidemiology of acquired aplastic anemia. Haematologica 93:489-492, 2008

90. Taj M, Shamsi TS, Ansari SH, et al: Epidemiologic and HLA antigen profile in patients with aplastic anemia. J Coll Physicians Surg Pak 24:549-552, 2014

91. Ali N, Moiz B, Bin Azhar W, et al: Carrier detection for beta-thalassemia trait in general Pakistani population: A way forward. Hematology 17:237-240, 2012

92. Aljurf M, Zaidi SZ, Hussain F, et al: Status of hematopoietic stem cell transplantation in the WHO Eastern Mediterranean Region (EMRO). Transfus Apheresis Sci 42:169-175, 2010